Porton Pharma Solutions Ltd.

China-based global CDMO (listed on ChiNext) with dedicated TIDES platform for peptide and oligonucleotide drug development and manufacturing. Over 4,200 employees with 18 operations and commercial offices across US, EU, and China. Provides end-to-end integrated API and drug product CDMO solutions for peptide drugs from preclinical to commercial launch. R&D centers and GMP production bases in Shanghai and Chongqing including HP (OEB 5) capabilities. Services cover process development, toxicology batch manufacturing, characterization, formulation, analytical method development, stability studies, and global regulatory filing support.

Porton Pharma Solutions Ltd. is listed as a cdmo in the peptide supply chain, serving Asia markets from China. As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. Verification is supported by 2 independent sources, including documentation review and cross-referencing against public records. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.